This announcement is a separate document:
华东医药：国盛证券有限责任公司关于华东医药股份有限公司2022年限制性股票激励计划预留授予限制性股票第一个解除限售期解除限售条件成就事项之独立财务顾问报告
Huadong Pharmaceutical: Independent Financial Advisory Report of Guosheng Securities Co., Ltd. on the achievements of Huadong Pharmaceutical Co., Ltd. in the 2022 Restricted Stock Incentive Plan to reserve and grant restricted shares for the first time to lift the sales restriction period and lift the sales restriction conditions
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated